Over the past decade, the detection and analysis of liquid biopsy biomarkers such as
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced …

Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …

Liquid biopsy has seen tremendous progress over the past decade as it represents a
potential innovative solution to several limitations of current cancer management. By …

Liquid biopsies as a minimally invasive approach have the potential to revolutionize
molecular diagnostics. Yet, although protocols for sample handling and the isolation of …

Liquid biopsy stands as an innovative instrument in the realm of precision medicine,
enabling non-invasive disease diagnosis and the early detection of cancer. Liquid biopsy …

Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Liquid biopsy is based on minimally invasive blood tests and has a high potential to
significantly change the therapeutic strategy in cancer patients, providing an extremely …

Liquid biopsy (LB) has emerged as a highly promising and non-invasive diagnostic
approach, particularly in the field of oncology, and has garnered interest in various medical …

Blood-based liquid biopsies provide a minimally invasive alternative to identify cellular and
molecular signatures that can be used as biomarkers to detect early-stage cancer, predict …

The field of cancer diagnostics has recently been impacted by new and exciting
developments in the area of liquid biopsy. A liquid biopsy is a minimally invasive alternative …